McKesson Corporation (NYSE: MCK) — The Best Toll Road on the Drug Highway, Now Selling Off Its Side Streets

Report date: June 13, 2026 Price reference: ~$784 (NYSE close, 2026-06-12) | Market cap: ~$94B | EV: ~$101B | Shares: ~120M | FY-end: March 31

⚡ Claude’s Take

This block is the author’s own subjective opinion. It is general information, not investment advice. The analysis that follows takes no position and carries no price target — it discusses valuation only as embedded expectations and scenarios.

Verdict: HOLD — the highest-quality of the three drug-distribution toll-takers, at a full-but-not-egregious price; accumulate on weakness below ~$690–700. Conviction: medium-high on the business, medium on the entry. The directional zone I’d anchor to is ~16–18.5x FY2027 adjusted EPS of ~$44.2, i.e. a fair band of roughly $720–$820, with genuine value emerging below ~$690 (≈15.5x, the kind of level the stock would only reach on a growth scare) and froth above ~$900–950 (where it printed its 52-week high at >22x forward — a multiple no thin-margin distributor durably deserves).

McKesson is the deserved premium name among the Big-3 (with Cencora and Cardinal Health) that intermediate ~90%+ of US prescription drugs — a textbook Greenwald economies-of-scale + customer-captivity moat where the sub-2% operating margin is the barrier to entry. It is the #1 by share (~one-third of US pharma distribution), earns the highest returns on capital in the group (management-cited ROIC ~34%, genuinely exceptional), runs the lowest leverage (~0.7x net debt/EBITDA), and has the most disciplined capital-allocation record: it has compounded adjusted EPS ~17% a year since FY2020, shrunk its share count ~23% in five years, and returned ~$23B to holders. FY2026 was a banner year — revenue +12% to $403B, adjusted EPS +18% to $39.11, FCF $5.4B — and management guides FY2027 to $43.80–44.60 (+12–14%) against a reaffirmed 13–16% long-term EPS algorithm. On top of the distribution flywheel sits a genuinely differentiated, higher-margin growth engine the market under-appreciates: the oncology & multispecialty platform (US Oncology Network, Florida Cancer Specialists/Core Ventures, PRISM Vision retina) and the ~22%-operating-margin Prescription Technology Solutions (access/affordability) business.

So why only HOLD, and why the framing is “wonderful business, fully-priced, with the EPS engine quietly leaning on financial engineering” rather than a table-pound? Three things. (1) The 13–16% algorithm is increasingly buyback-assisted, not operating-driven. FY2027 guides adjusted operating profit to +8–12% but EPS to +12–14% — the wedge is a ~$5B buyback taking share count from ~124M to ~116–118M, itself turbo-charged by one-time proceeds from the MedSurg carve-out. That is value-accretive at ~17x, but it means the “growth” multiple is partly buying a shrinking-denominator trick that decelerates once the proceeds are spent. (2) The oncology MSO roll-up is the same top-of-cycle capital wager Cencora is making — buying physician practices at multiples PE already inflated — layered on a franchise that already carries CVS at ~24% of revenue (the single largest idiosyncratic risk in the group) and ~73% in the top ten. (3) The alignment optics are poor: insiders own <1%, there are zero open-market insider buys in the five-year Form 4 record (291 filings, 190 sales, not one purchase), and the CEO just consolidated the Chairman title. The single fact that would flip me bullish: a CVS contract renewal on confirmed-stable economics into the 2030s plus evidence the oncology platform is compounding operating profit double-digit organically post-acquisition lap. The single fact that would flip me bearish: a CVS renegotiation/loss, or the EPS algorithm revealed as buyback-dependent as operating growth slides toward the low-single digits.

1. Executive Summary

McKesson Corporation (NYSE: MCK) is the largest of the three US pharmaceutical distributors — McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health — that together move north of 90% of the prescription drugs sold in America. In fiscal 2026 (ended March 31, 2026) it distributed $403.4 billion of revenue at a 3.6% gross margin and a ~1.5% GAAP operating margin, converting that into $6.2 billion of operating cash flow on a trivial ~$0.7 billion of capex. This is a hyper-scaled, razor-thin, capital-light logistics utility: the company keeps about three-and-a-half cents of gross profit and under two cents of operating profit per revenue dollar, and the investable signal is gross-profit-dollar growth, segment mix, and per-share compounding — not the headline revenue number.

The business earns its keep through the strongest archetype in Greenwald’s taxonomy — economies of scale reinforced by customer captivity — operating through a thin-margin cost structure that is itself the entry barrier. No one can profitably replicate a national, automated, auto-replenishment distribution network to skim a fraction of a percent. The proof is in the returns on capital (not on sales): management cites ROIC of ~34% for FY2026, comfortably the highest of the Big-3 (Cencora ~12–14%, Cardinal ~17%), against a ~7–9% WACC. The three-firm share structure (MCK ~35% / COR ~30% / CAH ~25%) has been stable for over a decade, and McKesson sits atop it.

Three forces define the forward debate. First, the quality-of-the-growth question. FY2026 adjusted EPS grew 18% (to $39.11) and FY2027 is guided to +12–14% ($43.80–44.60), but the EPS line is increasingly outrunning operating profit (guided +8–12% in FY27) on the back of a relentless buyback — FY2027 contemplates ~$5B of repurchases taking diluted shares to ~116–118M (from ~124M). Genuinely value-accretive, but it tilts the “growth stock” framing toward a per-share-compounding-machine framing. Second, the portfolio reshaping. McKesson has spent two years sharpening its focus: it completed its exit from Europe (selling its Norway business in January 2026 for a ~$480M gain), and it is separating the Medical-Surgical Solutions segment into an independent company — Apollo agreed to a ~13% minority stake for $1.25B, implying a ~$13B enterprise value, with the proceeds earmarked principally for buybacks. Simultaneously it is doubling down on the higher-margin oncology & multispecialty platform (US Oncology Network, Florida Cancer Specialists via Core Ventures, PRISM Vision retina) and the high-margin Prescription Technology Solutions (RxTS) access/affordability business. Third, concentration and capital-cycle risk. CVS Health is ~24% of revenue (top ten ~73%), and the oncology roll-up is being executed at a hot point in the physician-practice capital cycle.

At ~17.7x forward adjusted EPS and ~13–14.6x EV/EBITDA, McKesson trades at a deserved premium to Cencora (~15.8x) and roughly in line-to-above Cardinal (~16.6x) — its higher ROIC, lower leverage, and cleaner balance sheet justify the gap. On its own ten-year history the P/E sits around the 42nd percentile (mid-range), while P/S sits at the 87th percentile (distorted upward by the pass-through revenue line). The stock has pulled back ~22% from a frothy $999 high. This memo takes no position and sets no target; the analysis below frames what the price is underwriting and where the thesis breaks on each side.

2. Business Overview

What McKesson does

McKesson sits in the middle of the pharmaceutical supply chain. Manufacturers (Lilly, Novo, Pfizer, Amgen, the generics houses) sell to McKesson; McKesson warehouses, breaks bulk, and delivers — usually on a next-day, auto-replenishment basis — to the tens of thousands of points of care that dispense or administer drugs: retail pharmacy chains (above all CVS), independent pharmacies, mail-order/PBM pharmacies, hospitals and health systems, physician practices (especially oncology and other specialties), and long-term-care and alternate-site pharmacies. It distributes “approximately one-third of the pharmaceuticals in North America” (management’s framing) and is, functionally, critical national infrastructure.

The economic engine is not a simple cost-plus markup. It has two distinct profit mechanics:

• Brand drugs are largely distributed under fee-for-service distribution-service agreements (DSAs) with manufacturers — McKesson is paid a (largely fee-based, partly percentage-of-WAC) amount for logistics and data services, partially decoupling its dollar economics from drug list prices. This is exactly why management guides on operating profit, not revenue: when a manufacturer cuts a list price (as the IRA increasingly forces), revenue falls but the fee can be renegotiated to preserve dollar profit. In FY2026, management explicitly noted it “successfully navigated the first wave of branded pharmaceutical price changes related to the Inflation Reduction Act” with no operating-profit impact, even as those declines reduced North American Pharmaceutical revenue growth by ~3 points in Q4.
• Generics are distributed on a buy-and-hold basis, where McKesson captures buy-side sourcing margin and manufacturer rebates. Generic-sourcing scale is a genuine competitive variable, and McKesson runs a global sourcing operation (including the Clarus/RxC and ClarusONE generic-sourcing venture historically operated with CVS).

Layered on top is a growing book of higher-margin specialty and value-added services: specialty distribution to oncology and other physician offices (Part B, physician-administered drugs); the US Oncology Network (the largest community-oncology platform in the country); biopharma access/affordability services; data and insights (Ontada); and clinical research (Sarah Cannon Research Institute, SCRI).

Segment structure and FY2026 economics

Effective fiscal 2026, McKesson reorganized into four reportable segments (from the prior US Pharmaceutical / RxTS / Medical-Surgical / International structure), explicitly to “increase transparency to our growth areas and better align reporting with how we operate the business and how we allocate capital.” On the FY2026 basis (10-K, ended 3/31/26):

Source: MCK FY2026 10-K segment tables. Segment revenue figures are reportable-segment “Revenues, net”; total consolidated revenue per the income statement was $403.4B. Margins computed by Claude.

The single most important structural fact in this table: North American Pharmaceutical is ~84% of revenue and ~50% of profit at a ~1.1% margin, but the other three segments throw ~50% of the profit at margins 2–20x higher. RxTS is the crown jewel — ~22% operating margin on $4.8B of revenue — and Oncology & Multispecialty is the growth engine (+50% op profit). The margin lives in services and specialty, not in moving boxes. This is the entire investment story: McKesson is using the cash flow and customer relationships of a 1%-margin distribution utility to fund a higher-margin, faster-growing services and specialty layer.

Customers, suppliers, and recurring-revenue character

Revenue is highly recurring and non-discretionary — drugs are repeat-purchase necessities, and McKesson is typically the primary or sole distributor under auto-replenishment. But the concentration is severe and is the franchise’s defining idiosyncratic risk (covered in Section 4 and Section 9): sales to CVS Health were ~24% of total consolidated revenue in FY2026 (and ~21% of trade receivables), and the ten largest customers were ~73% of revenue (~43% of receivables). The CVS pharmaceutical-distribution partnership was extended in fiscal 2023. On the supply side, by contrast, there is healthy diversification across thousands of manufacturers.

Verdict (Business Overview): A genuine utility-like, recession-resistant logistics franchise with deeply recurring volumes and a high-margin specialty/services overlay that is the real source of value creation — but one whose reported revenue is a misleading pass-through gross number, whose distribution profit pool is razor-thin, and whose customer base is dangerously concentrated in a single payer-retailer (CVS). Read the segment operating-profit lines and the specialty mix; ignore the $403B headline.

3. Industry Dynamics

Structure: a protected three-firm oligopoly

US pharmaceutical distribution is one of the cleanest oligopolies in large-cap America. Three firms intermediate 90%+ of prescription drugs flowing from thousands of manufacturers to hundreds of thousands of dispensing/administering points. The structure has been remarkably stable for more than a decade — rough shares of MCK ~35% / COR ~30% / CAH ~25%, with the balance in regional and specialty players. This is not a market where share sloshes around; it is a mature, consolidated, share-stable system, and McKesson is the leader.

The industry’s defining feature — and the source of both its low margins and its high barriers — is bilateral scale economics on razor-thin spreads. Distributors add value by (a) consolidating thousands of manufacturer SKUs into single daily deliveries, (b) financing the channel’s working capital (they pay manufacturers and collect from customers on different cycles — McKesson runs deeply negative trade working capital, a low-cost float), © providing ordering technology, data, and regulatory/DSCSA-serialization compliance, and (d) sourcing generics at scale. The Healthcare Distribution Alliance estimates the channel adds ~$78–80B of annual value to the system at well under 1% of brand drug cost — the distributors capture only a sliver of the value they create, which is precisely why the system is hard to disrupt: there is almost no margin to attack.

The economics are structurally attractive for incumbents in ways the margin line hides:

• Negative working capital. Distributors collect from customers faster than they pay manufacturers, so growth is partly self-funding and the float is an enormous, low-cost financing source. McKesson cited working-capital efficiency (including AI-driven inventory planning) as a meaningful contributor to its $6.2B FY26 operating cash flow.
• Trivial capex. At ~0.2% of sales (~$0.7B on $403B), this is among the most capital-light “industrial” models in existence — incremental volume drops through at very high incremental returns on tangible capital. This is the mechanical reason ROIC can be ~34%.
• Volume tailwind. US prescription volume grows mid-single-digits structurally (aging demographics, chronic disease), and the specialty/biologic mix shift raises dollar value per script even as unit growth moderates. GLP-1s have been an enormous (if low-margin) volume engine — McKesson’s GLP-1 distribution revenue was $53B in FY2026 (+27%).

The threats — real but mostly second-order

The “disruption is coming” narrative on drug distribution has been wrong for fifteen years, but the threats deserve specific treatment because some are now live:

1. IRA / list-price deflation. Medicare price negotiation and the broader manufacturer move to lower WAC list prices cut the revenue line directly. To the extent distributor margin is a percentage of WAC, this is a margin headwind — but most brand economics are fee-for-service DSAs renegotiable to preserve dollar fees. McKesson states it navigated the first IRA wave with no operating-profit impact. This is the most important industry uncertainty, but the evidence so far supports the “revenue-optics, not profit” reading (see Section 10/Section 14).

2. Biosimilar disintermediation in Part D mail. As brands convert to biosimilars, mail-order pharmacies/PBMs can in-source the biosimilar and bypass the wholesaler. Management is explicit this is already in the model (a low-margin revenue hit, not a meaningful profit hit), and that the offsetting Part B (physician-administered) dynamic is actually beneficial to McKesson, because its US Oncology Network GPO and specialty footprint can drive rapid, uniform adoption to a biosimilar or innovator — value manufacturers pay the GPO/distributor for. 89 biosimilars approved / 72 launched as of the Q4 call. The bears’ watch item: leakage of disintermediation from low-margin Part D mail into high-margin Part B specialty. No evidence yet.

3. ASP compression in community oncology. A subtler, McKesson-specific risk: physician practices in the US Oncology Network are reimbursed on ASP+ (average selling price). As high-cost oncology drugs convert to biosimilars and prices fall, ASP-based reimbursement dollars per unit shrink — squeezing the practice (and McKesson’s economics) unless offset by volume, mix, and the network-effect adoption value described above. Management acknowledges the dynamic is “more complicated in the community setting.”

4. Amazon Pharmacy / Cost Plus / direct-to-patient, and payer in-sourcing. New DTC and manufacturer-direct channels (Lilly Direct) reshuffle dispensing but still need physical logistics; the most credible structural tail risk is a giant integrated payer (CVS/Caremark, Optum, Evernorth) deciding to self-distribute — which is why CVS being a ~24%-of-revenue customer matters. To date the economics of self-distribution at sub-2% margin have not justified the capital.

Verdict (Industry): Structurally GOOD — for the incumbents, and best of all for the leader. A consolidated, share-stable, recession-proof oligopoly with self-funding growth and trivial capital intensity, where the very thinness of the margin is the moat. It will never be a high-margin industry, and it carries real second-order disruption risks (IRA deflation, Part B biosimilar leakage, ASP compression, payer in-sourcing) — but as a place to deploy capital over a decade, the structure is attractive. In Marathon capital-cycle terms, core distribution is a low-supply-growth, high-barrier system; the caution is reserved for where the incumbents are now redeploying their cash (oncology MSOs — see Section 4 and Section 6).

4. Competitive Position

Naming the moat

In Greenwald’s taxonomy, McKesson’s core distribution moat is the strongest archetype: economies of scale reinforced by customer captivity, operating through a thin-margin cost structure that is itself the entry barrier.

• Economies of scale. Distribution is a dense fixed-cost network (automated DCs — e.g., the new AI/robotics-powered Montreal facility — fleet, IT, DSCSA-serialization infrastructure, generic-sourcing volume). McKesson is the largest of the three, spreading these costs over the most throughput; a sub-scale entrant cannot match the unit cost on a fraction-of-a-percent margin, and generic sourcing in particular rewards the largest buyer.
• Customer captivity. Customers are bound by deep operational integration — auto-replenishment, ordering systems, inventory management, GPO contracts, and the simple fact that McKesson is often the sole supplier to a pharmacy or practice. Switching distributors is operationally disruptive for a low-margin pharmacy with no incentive to risk supply continuity to save basis points. In the oncology platform, captivity is deeper still: McKesson doesn’t just supply the practice, it increasingly owns/operates the management layer (US Oncology Network), embedding software (ambient AI scribes used by 1,900+ providers), data (Ontada), and research (SCRI).
• The margin is the moat. Because the incumbents capture so little of the value they create, there is almost no profit umbrella under which a disruptor could undercut them. You cannot win a price war to capture ~1% operating margins.

The financial proof points are the strongest in the group: management-cited ROIC ~34% (vs COR ~12–14%, CAH ~17%), a decade of share stability, pricing power sufficient to “recoup the value” of IRA list-price changes through DSA renegotiation, and the highest segment-operating-margin mix (RxTS at ~22%). Morningstar-style framing would call the core a narrow moat; we agree it is real and durable, but not wide, because the customer captivity is offset by the customers’ own scale (CVS at ~24% of revenue has enormous bargaining power, as periodic contract renegotiations demonstrate).

MCK vs. Cencora vs. Cardinal Health

Sources: company filings; public market data and consensus for COR/CAH. Figures approximate, for relative positioning.

McKesson is the deserved premium name — the highest ROIC, the lowest leverage, the richest segment-margin mix, and the most aggressive buyback. Its ~2-turn forward-P/E premium to Cencora is rational, not a free lunch: COR carries lower ROIC, higher (and recently doubled) leverage from its own MSO roll-up, and a comparable customer-concentration overhang (Walgreens ~25%). Cardinal is the more cyclical recovery story. Among the three, MCK is the highest-quality, COR the cheapest, CAH the most cyclical.

The oncology-MSO question — moat extension or capital-cycle trap?

The central competitive-position debate is not core distribution; it is where McKesson is taking the franchise next. Management is scaling Management/Practice services in high-value Part B specialties — the US Oncology Network (oncology; added 570+ providers in FY26, the largest net increase since 2010), Florida Cancer Specialists capabilities via Core Ventures, and PRISM Vision (retina/ophthalmology; +~20% providers). The strategic logic is coherent and defensive: these specialties are exactly where McKesson’s specialty distribution and GPO economics live, so owning/operating the practice deepens customer captivity, locks in drug volume, and captures higher-margin services and data fees on top of the distribution spread. As brands convert to biosimilars in Part B, the network’s adoption-driving power is value manufacturers pay for. McKesson has the longest track record here of the three (US Oncology Network predates Cencora’s OneOncology by years), which is a genuine edge.

The skeptical read, through a Marathon capital-cycle lens, is the same one we applied to Cencora: McKesson is rolling up physician practices at the same time private equity has bid those assets to rich multiples — in several cases the distributor is effectively PE’s exit. PRISM + Core Ventures contributed ~34% of Oncology & Multispecialty operating-profit growth in FY26; strip acquisitions and organic segment op-profit growth was ~13% (healthy, but below the 50% headline). The bet may well work — early integration commentary is encouraging and McKesson’s incumbency is real — but it is a separate, higher-risk capital wager layered on top of the distribution moat, and (per Section 6) it is consuming the cash that historically funded buybacks.

Verdict (Competitive Position): DURABLE narrow moat in the core — the best in the group — with a credible but capital-cycle-exposed bet on the edge. The distribution franchise is a real, scale-and-captivity advantage that will persist, and McKesson’s ROIC/leverage profile proves it executes the model better than its peers. The oncology MSO expansion is strategically logical and McKesson is better-positioned than Cencora to win it, but it is being built at a hot point in the capital cycle and the burden of proof on returns sits with management.

5. Growth History and Forward Opportunities

The history: from a near-death opioid year to a 17% compounder

McKesson’s recent history splits cleanly. FY2021 was the trough — a -$5.0B operating loss and -$28.26 GAAP diluted EPS, driven by the ~$8.1B pre-tax opioid litigation charge taken to reach the national settlement. Everything since has been a steady, high-quality compounding story:

Revenue/GAAP figures per EDGAR XBRL (10-K). Adjusted-EPS series approximate from company releases; FY26 $39.11 and FY27 guide per Q4 FY26 call (May 7, 2026). Adjusted EPS excludes intangible amortization, opioid/litigation charges, restructuring, and certain gains.

The picture: revenue +69% over five years, adjusted EPS roughly doubled, and the share count fell 23%. Management states adjusted EPS has compounded ~17%/yr since FY2020 and it has returned ~$23B to holders over that span. This growth has been high-quality in its drivers: (a) secular mid-single-digit US prescription-volume growth; (b) a continuous mix shift toward specialty (oncology, GLP-1s, biosimilars), raising gross-profit dollars; © generic-sourcing scale; (d) the negative-working-capital float financing growth; (e) the higher-margin RxTS and oncology platforms growing double-digit; and (f) a steady, large buyback. Part of it is acquired (Core Ventures, PRISM); the organic specialty-volume and RxTS pieces are the highest-quality.

FY2026 detail and the FY2027 setup

FY2026 was, in management’s words, a year of “exceptional financial performance”: revenue +12%, adjusted operating profit +15% to $6.5B (three of four segments double-digit), adjusted EPS +18% (+20% ex prior-year Ventures gains), FCF $5.4B, ROIC ~34%. Crucially, operating expenses as a percentage of gross profit fell 293 bps — real operating leverage from automation/AI investment, not just buyback math.

FY2027 guidance ($43.80–44.60, +12–14%; +14–16% ex one-time items) rests on:

• North American Pharmaceutical: revenue +4–8%, op profit +5.5–9.5% (above the 5–8% LT target) — stable utilization, specialty growth (incl. health systems), and continued (if lumpy) GLP-1 growth, against the headwind of IRA list-price declines and lapping the Rite Aid revenue and a large onboarded customer.
• Oncology & Multispecialty: revenue +14.5–18.5%, op profit +13.5–17.5% — provider-network expansion + the PRISM/Core Ventures lap; organic growth “in the middle of the 13–16% target range.”
• RxTS: revenue +2.5–6.5%, op profit +11–15% — the 3PL revenue (~55% of segment) is lumpy, but the high-margin access/affordability technology services (incl. GLP-1 support) drive the profit at the upper end of the 10–13% target.
• Medical-Surgical: revenue +1–6%, op profit flat to +4% — the low-growth segment, soon to be deconsolidated.

Forward opportunities

• Specialty and Part B biosimilars — the richest vein: physician-administered specialty + the biosimilar conversion wave where McKesson’s GPO/MSO presence makes conversion accretive.
• Oncology/multispecialty platform expansion — more providers and practices (Cancer Care Northwest, Retina Macula Institute added FY26/early FY27), plus the data (Ontada) and research (SCRI) flywheel.
• RxTS / biopharma access-and-affordability technology — record 3.4M patients supported in FY26, ~$10B of patient savings; an opex-light, ~22%-margin, technology-leverage story.
• AI/automation productivity — AI-driven inventory planning (working-capital release) and warehouse robotics (Montreal) as a margin/efficiency lever.

Verdict (Growth): High-quality growth, but with the EPS line increasingly reliant on the buyback. The compounding is real and durably-sourced (specialty mix + volume + RxTS/oncology + float). But the FY27 wedge between +8–12% operating-profit growth and +12–14% EPS growth is the buyback — itself temporarily turbo-charged by MedSurg carve-out proceeds. The operating growth is good; the per-share growth is good-plus-financial-engineering, and the engineering decelerates once one-time proceeds are spent.

6. Financial Quality

Margins, returns, and the “negative equity” question

McKesson’s income statement is the definition of high-volume/thin-margin: FY2026 gross margin 3.6%, GAAP operating margin ~1.5%, net margin ~1.2%. These look alarming until you remember the model: the denominator is a ~$403B pass-through, and the relevant metric is return on capital, not return on sales. On that basis the business is exceptional — management-cited ROIC ~34%, the product of fat asset turns (capex ~0.2% of sales) and negative working capital.

The most-asked question is the negative stockholders’ equity (-$2.2B at 3/31/26, negative every year since at least FY2022). This is not a solvency problem — it is a buyback artifact. McKesson has repurchased far more stock (cumulatively) than it has retained in earnings, driving book equity below zero. The correct read is that book value is meaningless here and ROE is undefined; use ROIC and FCF. A company generating ~$5–6B of FCF on ~$5B of net debt with an A-/A3 investment-grade rating and ~$9B of liquidity is not financially fragile — it is financially optimized (some would say financially engineered).

Cash flow — the real engine

EDGAR XBRL (cash-flow statement) + Q4 FY26 call. Capex/FCF vary with the day-of-week a quarter closes (management’s caveat); FY26 FCF of $5.4B and FY27 guide of $4.5–4.9B per the call.

FCF conversion of GAAP net income is strong (FCF ~$5.4B vs GAAP NI $4.76B FY26 — over 100%, helped by working-capital efficiency and the SBC add-back). The FY27 FCF guide steps down ~13% (to $4.5–4.9B) despite +8–12% operating-profit growth — driven by working-capital timing and continued reinvestment, per management. That deceleration deserves monitoring, but the multi-year FCF moving-average is rising in line with operating performance.

Quality-of-earnings flags

1. GAAP vs. adjusted wedge. FY26 GAAP diluted EPS was $38.38 vs adjusted $39.11 — unusually close, because FY26 GAAP was flattered by ~$480M of Norway divestiture gains and a ~$182–210M LIFO credit, partly offset by a $108M opioid charge and RNCI adjustments. In a normal year the adjusted figure sits meaningfully above GAAP (intangible amortization from the acquisition spree, opioid/litigation, restructuring). Watch the add-backs; the FY26 GAAP/adjusted convergence is partly a coincidence of offsetting one-timers.
2. Discrete tax benefits. Q4 FY26 carried $158M of discrete tax benefits (affiliate liquidation), pulling the quarterly rate to 12.1%; FY27 guides the rate up to 17–19%, a normalization headwind embedded in the EPS guide.
3. SBC. Modest for the scale (stock awards ~$0.3–0.4B), not a material dilution driver — the buyback overwhelms it (shares fell every year).
4. The buyback is a chunk of EPS growth. As noted, FY27 EPS growth (+12–14%) exceeds operating-profit growth (+8–12%); the difference is the ~$5B repurchase shrinking the count ~6%.
5. Opioid. A $5.7B accrued liability at 3/31/26 (the ~$7.4B national settlement, payable over ~18 years), now tapering (~$400–500M/yr cash, FY26 P&L charge just $108M). Well-provisioned and second-order — materially smaller relative to McKesson than to its smaller peers.

Verdict (Financial Quality): Economics improve with scale — emphatically. The ~34% ROIC, >100% FCF conversion, trivial capex, and negative working capital are the financial signature of a genuinely advantaged business. The caveats are about presentation and durability, not health: negative book equity is a buyback artifact (ignore it), the EPS algorithm leans on the buyback, FCF is guided down in FY27, and a normalizing tax rate is a FY27 headwind. None of these is a red flag; together they argue for valuing the business on operating-profit and FCF growth, not on the headline EPS algorithm.

7. Capital Allocation

The framework and the record

Management articulates a consistent three-pillar framework: (1) invest in growth (organic + on-strategy M&A with good financial returns) first; (2) return capital via a growing dividend and (primarily) buybacks; (3) maintain a strong investment-grade rating underpinning it all. The record backs the rhetoric: ~$23B returned since FY2020, a ~17% adjusted-EPS CAGR, ROIC ~34%, and a 23% reduction in the share count over five years. This is, on the numbers, best-in-class capital allocation among the Big-3 — McKesson buys back more, more consistently, at a higher ROIC, and with less leverage than its peers.

Buybacks dominate. FY26 repurchases were $4.75B (including a $2.25B accelerated share repurchase launched March 2026), and the Board added $5B of authorization in April 2026 (total ~$7.7B). FY27 contemplates ~$5B of repurchase, taking diluted shares to ~116–118M. The dividend is deliberately small (~$3.28/yr forward, ~0.4% yield, ~8% payout) and grows roughly in line with earnings — McKesson is unambiguously a buyback-first capital-return story.

M&A has been disciplined and on-strategy — the oncology/multispecialty tuck-ins (Core Ventures/Florida Cancer Specialists, PRISM Vision, Rx Savings Solutions earlier, CardX/Clarus generics venture) cluster around the specialty/services growth pillars rather than empire-building. The caution (per Section 4) is price: these MSO assets are being bought at a hot point in the physician-practice capital cycle. McKesson’s track record of integration and its longer oncology incumbency mitigate but do not eliminate the Marathon mean-reversion risk.

The portfolio reshaping — a genuine value-creation lever

The two-year deconglomeration is the clearest evidence of disciplined allocation:

• Europe exit, completed. McKesson sold its Norway business in January 2026 (~$480M gain), finishing a multi-year, value-conscious exit from a structurally inferior European distribution market.
• Medical-Surgical Solutions separation. McKesson is carving out and (planned) IPO-ing its MedSurg segment. Apollo agreed to a ~13% minority stake for $1.25B, implying a ~$13B enterprise value — a rich valuation for an ~$10.6B-revenue / $938M-op-profit business (~14x op profit) that validates the sum-of-the-parts logic. MedSurg has raised an independent capital structure ($1B Term Loan A + $1B revolver + up to $2.25B additional term loans), and the proceeds flow back to McKesson Corp to fund — principally — share repurchases. This is a textbook “separate the lower-multiple business, monetize it, and shrink the share count” value play; the only quibble is that recycling proceeds into buybacks (rather than the higher-return oncology pipeline) is the safe use, and the EPS benefit is one-time.

Incentive alignment and insider behavior — the soft spots

The compensation design is well-constructed and tied to the right metrics:

• Annual incentive (MIP): adjusted EPS 50% / adjusted operating profit 25% / FCF 25%, with a downward-only non-financial modifier. FY26 paid 140% of target.
• Long-term (PSUs, new FY26 grant): 3-yr cumulative adjusted EPS 60% + 3-yr average ROIC, with relative TSR as a ±20% modifier (vs a custom 14-company healthcare comparator group — COR, CAH, CVS, Cigna, Elevance, UNH, JNJ, Pfizer, Sanofi, Teva, Viatris, Henry Schein, Kroger, +1). RSUs are 40% of LTI. The prior-vintage PSUs paid 146% (cum adj EPS 143%, ROIC 99%, rTSR at the 86th percentile = 200%). Including ROIC and rTSR in the plan is a genuine positive — it disciplines the buyback-fueled EPS growth against returns and relative performance.
• Say-on-pay: ~91% at the most recent vote — solid, not stellar.

But the alignment optics are poor on two counts. (1) Insiders own <1% of the company (all directors and officers as a group: ~73,455 shares; the CEO ~28,000), with the register dominated by passive index holders (BlackRock 7.9%, Vanguard 7.8%). (2) There are ZERO open-market insider purchases (code P) in the entire five-year Form 4 record — across 291 filings, the activity is 190 open-market sales, 308 option/RSU exercises, 159 tax-withholdings, and 134 grants, but not a single conviction buy. The classic “all-grant-and-sell” pattern. Combined with the CEO’s May 2026 consolidation of the Chairman role (mitigated by an empowered Lead Independent Director, Dominic Caruso), this is a mild governance/alignment negative — competent, shareholder-friendly capital allocation, but no personal skin-in-the-game signal.

Verdict (Capital Allocation): Among the best in large-cap healthcare — with a soft governance underbelly. Disciplined, ROIC-aware, buyback-led, with a value-creating portfolio reshaping (Europe exit + MedSurg monetization) and incentive metrics tied to EPS/ROIC/rTSR. The negatives are alignment optics (sub-1% ownership, zero open-market buys, combined Chair/CEO) and the capital-cycle risk on the oncology roll-up — not the allocation discipline itself.

8. Changes and Headwinds — Last Two Years

Strategic / structural:

• Four-segment reorganization (FY26) — North American Pharmaceutical, Oncology & Multispecialty, RxTS, Medical-Surgical — for transparency into the growth platforms. Strengthens the thesis (better disclosure of where the margin/growth is).
• Medical-Surgical separation announced (one year ago) and advancing — Apollo minority (~13% at ~$13B EV), independent financing, planned IPO. A focus-and-value-unlock move; the dominant corporate event.
• Europe fully exited (Norway sold Jan 2026, +$480M gain) — completes a multi-year simplification.
• Oncology platform scaled — Core Ventures (Florida Cancer Specialists) and PRISM Vision (retina) acquired/onboarded in Q1 FY26; US Oncology Network +570 providers (largest since 2010); Ontada data and SCRI research expanded.

Leadership / governance:

• CFO transition — Britt Vitalone (20 years, 8+ as CFO; oversaw a ~500% TSR and ~17% EPS CAGR) retired May 28, 2026; Kenny Cheung (ex-Sysco EVP & CFO) became CFO May 29, 2026. A meaningful but well-telegraphed change; Vitalone stays as strategic advisor through the MedSurg separation.
• Brian Tyler elected Chairman (May 2026) — now combined Chair + CEO; Dominic Caruso Lead Independent Director; Don Knauss leaving the board (age/tenure). Net governance: a modest weakening (combined Chair/CEO), partly offset by an empowered LID and a clean overall governance profile (annual elections, no pill, clawback, anti-hedge/pledge).

Headwinds / watch items:

• IRA branded price declines — first wave navigated in FY26 (revenue headwind, no profit impact); the full-year drag is embedded in the FY27 NA Pharma revenue guide (+4–8%).
• GLP-1 lumpiness — Q4 FY26 GLP-1 distribution revenue fell 4% sequentially (still +22% YoY); a low-margin but enormous revenue swing factor.
• FCF guided down ~13% in FY27 and tax rate normalizing to 17–19% — two embedded FY27 headwinds.
• Lapping Rite Aid revenue (Rite Aid bankruptcy) and a large onboarded customer in NA Pharma.
• Opioid — tapering but a multi-year cash outflow; $5.7B accrued.

Verdict (Changes & Headwinds): Net thesis-strengthening. The portfolio reshaping (MedSurg monetization, Europe exit, oncology scaling) is value-additive and well-executed; the leadership changes are orderly. The headwinds (IRA optics, GLP-1 lumpiness, FCF/tax normalization) are real but mostly transitory or margin-neutral. The one genuine weakening is governance (combined Chair/CEO + the long-standing alignment gap).

9. Risk Analysis (Risk Matrix)

The dominant risks are idiosyncratic-but-low-probability (CVS) and strategic-and-medium-probability (oncology capital cycle, buyback dependence). There is no near-term catastrophic-loss or total-loss risk — the balance sheet is investment-grade, the cash flows are utility-like, and the opioid tail is provisioned. The left-tail scenario is a valuation de-rating (EPS decel + multiple compression), not a solvency event.

10. Valuation Discussion (Embedded Expectations)

McKesson should be valued on earnings, FCF, and per-share compounding — never on revenue multiples (the $403B pass-through makes EV/Revenue of ~0.25x and P/S of ~0.23x meaningless; the 87th-percentile P/S in its own history is a pass-through-revenue artifact, not richness).

Where the multiple sits:

• ~17.7x FY27 adjusted EPS ($784 / ~$44.2 midpoint) and ~20x trailing FY26 adjusted EPS ($39.11).
• ~13–14.6x EV/EBITDA (~$101B EV / ~$6.9B EBITDA).
• ~5.7% FCF yield on FY26 FCF ($5.4B / ~$94B), ~4.8–5.2% on the FY27 guide ($4.5–4.9B).
• ~42nd percentile P/E vs its own ten-year history (mid-range — not stretched on earnings), with the stock ~22% below its $999 high.
• A deserved premium to COR (~15.8x) and roughly in line with/above CAH (~16.6x).

Embedded-expectations / reverse read: At ~17.7x forward with a ~5% FCF yield, and a long-term algorithm of 13–16% adjusted EPS growth, the market is underwriting roughly the low end of management’s algorithm — call it ~10–13% through-cycle EPS growth — which is achievable on the math (mid-single-digit operating-profit growth + ~5–6%/yr share-count reduction). The price is not demanding heroics. The risk to the embedded case is composition, not level: if the operating-profit growth fades toward low-single-digits (CVS pressure, ASP compression, oncology integration disappointing), the EPS algorithm becomes almost entirely buyback-driven — sustainable for a few years on the MedSurg proceeds, then decelerating — and a market that re-reads a “13–16% grower” as a “6–8% grower” would compress the multiple toward 13–14x, the double-discount left tail.

Scenario analysis (illustrative, not a forecast or target):

The skew from spot (~$784) is roughly balanced-to-favorable: the base band brackets the current price, the bull requires a “double hold” (upper-algorithm execution and a >20x multiple a thin-margin distributor rarely sustains), and the bear is a genuine ~20–30% drawdown but requires an operating-growth break, not just a wobble.

Verdict (Valuation): Fairly-to-fully priced for a high-quality compounder. Not cheap in absolute distributor terms, not expensive on earnings relative to its own history or its quality premium over peers. The valuation debate reduces to one question: is the 13–16% EPS algorithm durable operating growth, or buyback-dressed mid-single-digit operating growth? — see Section 14.

11. Variant Perception

Consensus view: McKesson is the blue-chip, best-in-class drug distributor — a defensive (~0.35 beta), recession-proof compounder with the best ROIC and balance sheet in the group, a clean opioid resolution, and a smart portfolio reshaping (MedSurg spin). Sell-side is constructive: ~13 buy/strong-buy, 3 hold, 1 sell; mean target ~$950 (though Barclays trimmed to $925 on June 10, 2026, still Overweight). Short interest is low (~2.3% of float). It is a crowded, well-owned, low-controversy long.

Strongest bull case: A wide-moat, share-stable oligopoly leader compounding adjusted EPS 13–16% with a 34% ROIC, a fortress balance sheet, and two under-appreciated higher-margin growth engines (oncology/multispecialty and ~22%-margin RxTS) layered on the distribution flywheel. The MedSurg monetization (~$13B EV validated by Apollo) unlocks value and turbo-charges the buyback; the company shrinks its share count ~5–6%/yr almost regardless of the macro. At ~17.7x — a market multiple for a above-market-quality compounder pulled back 22% from its high — this is a “quality at a reasonable price” long.

Strongest bear case: The 13–16% EPS algorithm is financial engineering dressed as growth — operating profit grows only high-single-digits, and the rest is a buyback temporarily juiced by one-time MedSurg proceeds and CVS pass-through volume. The franchise is dangerously levered to a single customer (CVS ~24%) whose contract and PBM strategy McKesson does not control, and to GLP-1 volumes that are low-margin and lumpy. The oncology roll-up is a top-of-cycle MSO bet (the same one Cencora is making, the same one that already burned Cencora once) being funded just as the easy buyback fuel runs out. ASP compression and Part B biosimilar dynamics quietly erode the highest-margin growth engine. Strip the engineering and you have a ~6–8% operating compounder trading at ~18x — too expensive — that de-rates to 13x.

The 3–5 assumptions that matter most:

1. CVS relationship stability through the contract cycle (the single biggest idiosyncratic variable).
2. Durability of double-digit organic operating-profit growth in Oncology & Multispecialty and RxTS post-acquisition-lap.
3. Whether IRA/ASP/biosimilar dynamics stay margin-neutral (revenue optics) or leak into the profit pool.
4. Sustainability of the ~5–6%/yr buyback once MedSurg proceeds are spent (i.e., FCF re-acceleration after the FY27 dip).
5. The terminal multiple the market assigns a thin-margin distributor running a buyback-heavy EPS algorithm (13–14x vs 18x vs 22x).

What would falsify each side: Bull is falsified by a CVS renegotiation/loss, a third year of decelerating organic oncology profit, or evidence of Part B biosimilar/ASP profit leakage. Bear is falsified by a CVS renewal on stable economics into the 2030s plus sustained double-digit organic operating-profit growth in the two high-margin segments and FCF re-accelerating above FY26 levels by FY28.

12. Fact vs. Interpretation

13. Open Questions

1. When does the CVS contract renew, and on what economics? The 10-K discloses the ~24% concentration and a FY23 extension but not the precise term or terms — the single most important unknown.
2. What is the organic (ex-acquisition) operating-profit growth trajectory of Oncology & Multispecialty once PRISM/Core Ventures fully lap, and what multiples is McKesson paying for new practices?
3. What is RxTS’s organic profit growth ex-GLP-1, and how exposed is its ~22% margin to GLP-1 program maturation/termination?
4. How much of the FY27 EPS growth is buyback vs operating, precisely, and what is the buyback cadence after MedSurg proceeds are deployed (FY28+)?
5. What is the post-separation McKesson margin/ROIC profile once the ~8.9%-margin MedSurg is deconsolidated (accretive to consolidated margin, but loses a profit stream)?
6. How does ASP-based reimbursement in community oncology hold up as the biosimilar wave compresses oncology drug prices?
7. What is new CFO Kenny Cheung’s capital-allocation and disclosure posture (any change from Vitalone’s playbook)?

14. What Must Be True

For the bull case (quality compounder at a reasonable price) to be right:

• US drug-distribution oligopoly stays share-stable and McKesson holds ~one-third share; CVS renews on stable economics into the 2030s.
• Oncology & Multispecialty and RxTS sustain double-digit organic operating-profit growth post-lap; the MSO acquisitions earn their cost of capital.
• IRA/ASP/biosimilar dynamics stay margin-neutral (revenue optics, not profit erosion).
• FCF re-accelerates after the FY27 dip, sustaining the ~5–6%/yr buyback beyond the one-time MedSurg proceeds.
• Falsification test: any of — a CVS contract loss/renegotiation that cuts the relationship’s economics; two-plus consecutive years of decelerating organic oncology/RxTS operating profit; clear evidence of Part B biosimilar/ASP profit leakage; or FCF failing to recover above ~$5.5B by FY28.

For the bear case (financially-engineered mid-single-digit grower at 18x) to be right:

• Operating-profit growth fades toward mid/low-single-digits as CVS pressure, ASP compression, and biosimilar dynamics bite, leaving the buyback doing most of the EPS work.
• The oncology MSO roll-up disappoints (integration, physician retention, returns) — a Cencora-style impairment or stranded capital.
• The market re-rates a buyback-heavy, single-customer-exposed thin-margin distributor toward 13–14x, producing a double-discount drawdown.
• Falsification test: sustained double-digit organic operating-profit growth in the two high-margin segments plus a CVS renewal on stable terms plus FCF re-acceleration — i.e., proof the algorithm is operating-driven, not buyback-driven.

15. Source Appendix

See the Source Appendix (Appendix B) below for the full source list with URLs and access dates.

This analysis takes no position and contains no price target; the only opinion expressed is the clearly-labeled Claude's Take block at the top, which is the author’s own independent view.

APPENDIX A — Standard Diligence Questionnaire — McKesson Corporation (NYSE: MCK)

Supplemental to the research memo. Answers grounded in the FY2026 10-K (filed 2026-05-08), Q4 FY2026 earnings call (May 7, 2026), the 2026 DEF 14A (filed 2026-06-12), EDGAR XBRL, and the Form 4 corpus. Fact / Interpretation / Assumption labeled where it matters.

General

What thoughtful questions have other investors asked about this company? The recurring questions (from the FY26 earnings calls): (1) GLP-1 sustainability — how durable is the $53B GLP-1 distribution revenue and the access/affordability program demand within RxTS? (2) Biosimilar economics — does the Part B/Part D biosimilar wave help or hurt, and how does ASP-based reimbursement in community oncology hold up as oncology drug prices fall? (3) Oncology organic growth — how much of Oncology & Multispecialty growth is organic vs PRISM/Core Ventures acquisitions? (4) FCF conversion — why is FY27 FCF guided down ~13% despite operating-profit growth? (5) MedSurg separation — value, timing, and use of proceeds. (6) Capital deployment — M&A vs buyback priorities once MedSurg proceeds arrive. The deepest unasked question this report presses: how much of the 13–16% EPS algorithm is operating growth vs buyback (Interpretation: FY27 EPS +12–14% vs OP +8–12% — the wedge is the repurchase).

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Neither — drug distribution is structurally non-cyclical (drugs are non-discretionary; beta ~0.35). FY26 was a strong year (adj EPS +18%, ROIC ~34%) but reflects secular volume/specialty growth and operating leverage, not a cyclical peak. (Interpretation.)

Driven by external environment or internal actions? Predominantly internal — specialty mix shift, operating-expense leverage (−293 bps opex/gross-profit in FY26), oncology platform scaling, and the buyback. External drivers (prescription-volume growth, GLP-1 demand) are favorable tailwinds but not cyclical swings.

How stable are revenues? Extremely stable and recurring (auto-replenishment of non-discretionary medicines), though the reported revenue line is volatile from low-margin pass-through effects (GLP-1 swings, IRA list-price declines) that do not move profit. Read segment operating profit, not revenue.

Outlook for products/services? Favorable — aging demographics, chronic-disease prevalence, specialty/biologic pipeline, and biosimilar conversion all support mid-single-digit volume growth with rising dollar-per-script.

How big is this market — growing, shrinking, domestic/international? US pharmaceutical distribution is a large (~$500B+ of drug flow), mid-single-digit-growing, predominantly domestic market (McKesson exited Europe in Jan 2026; remaining footprint is US + Canada). Structurally growing.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Stable — a decade-plus three-firm oligopoly (MCK ~35% / COR ~30% / CAH ~25%) with no share churn and high barriers. McKesson is the leader. (Fact/Interpretation.)

How profitable is the business (ROIC, ROE)? ROIC ~34% (management-cited, FY26) — exceptional and the highest of the Big-3. ROE is undefined/meaningless (negative stockholders’ equity from buybacks). Return on sales is tiny (~1.5% GAAP operating margin) — the wrong metric for a distributor.

How profitable is the industry — competitors, barriers? Low margins on sales but high returns on capital for incumbents; barriers are very high (the sub-2% margin itself, plus scale economics in logistics/generic-sourcing and customer captivity). Three national competitors plus regional/specialty players.

Can the business be easily understood? Yes — a logistics utility with a higher-margin specialty/services overlay. The nuance (read profit not revenue; negative equity is a buyback artifact) is the part first-time readers miss.

Can it be undermined by foreign low-cost labor? No — it is a domestic physical-logistics and regulatory-compliance network; not labor-arbitrage exposed.

Do brands matter? Minimally to end-demand (drugs are prescribed by molecule/manufacturer), but the McKesson relationship/contract and its GPO/network (US Oncology Network, Good Neighbor Pharmacy) create real captivity. The “brand” that matters is reliability and integration.

Nature of competition? Bilateral scale on thin spreads; competition is for contracts (e.g., the CVS, prior Walgreens/COR splits) and for specialty/oncology provider relationships — not day-to-day price wars.

Customers’ switching costs? High operationally (auto-replenishment, ordering/inventory systems, sole-supplier dependence, GPO contracts) — but offset at the top by customer scale (CVS ~24% has leverage). For owned oncology practices, captivity is deepest.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The negative working-capital float (a multi-billion-dollar low-cost financing source) and the customer-relationship/network intangibles (US Oncology Network, CVS contract) are economically valuable but not capitalized as such. (Interpretation.)

Off-balance-sheet liabilities? The opioid settlement is on-balance-sheet ($5.7B accrued, ~18-yr payout); redeemable noncontrolling interests / physician put-and-earn-out obligations in the oncology MSOs are a growing contingent claim (analogous to Cencora’s ~$1.8B) — disclosed but worth watching. (Fact/Interpretation.)

How conservative is the accounting? Reasonably — LIFO inventory (conservative in inflation), clear GAAP-vs-adjusted reconciliation, opioid fully accrued. Watch the adjusted-EPS add-backs (intangible amortization is a recurring cost of the acquisition model) and one-time gains (Norway +$480M, LIFO credits, discrete tax benefits) that flattered FY26 GAAP.

How CapEx-hungry? Among the least in large-cap — capex ~0.2% of sales (~$0.7B on $403B). Extremely capital-light; the source of the high ROIC.

Capital Allocation & Management

How much FCF, and how is it used? ~$5.4B FCF in FY26 (guided $4.5–4.9B FY27). Used overwhelmingly for buybacks ($4.75B FY26, ~$5B planned FY27), a small growing dividend (~$0.4B, ~0.4% yield), and on-strategy oncology/specialty M&A. Three-pillar framework: grow first, return capital, protect the IG rating.

Significant acquisitions recently? Core Ventures (Florida Cancer Specialists capabilities) and PRISM Vision (retina), both Q1 FY26 — on-strategy oncology/multispecialty. (Caution: top-of-cycle MSO multiples.)

Buying back shares? Yes, aggressively — share count 161M (FY21) → 124M (FY26) → guided 116–118M (FY27), a ~23%+ reduction. $7.7B authorization as of April 2026.

Issuing large amounts of new shares to insiders? No — SBC is modest (~$0.3–0.4B); the buyback dwarfs dilution.

Compensation policy of directors/management? Well-designed: MIP on adjusted EPS (50%)/adjusted OP (25%)/FCF (25%); PSUs on 3-yr cumulative adjusted EPS (60%) + 3-yr average ROIC, with relative TSR a ±20% modifier; RSUs 40% of LTI. Say-on-pay ~91%. CEO FY26 total ~$24.2M, ~93% variable. Ownership guidelines (CEO 6x salary).

Motivations of management? Shareholder-return-oriented on the numbers (ROIC in the plan, buyback-led). But alignment optics are weak: insiders own <1%, zero open-market purchases in 5 years (all grant-and-sell), and the CEO just consolidated the Chairman role. (Fact.)

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a US C-corp common stock (NYSE: MCK); standard 1099 dividends.

Dividend policy? Small and growing roughly with earnings — ~$3.28/yr forward, ~0.4% yield, ~8% payout. A buyback-first capital-return company; the dividend is a token.

How profitable is the business? ROIC ~34% (excellent on capital); ~1.5% GAAP operating margin (thin on sales — the wrong lens). FCF ~$5.4B.

Is net income diverging from cash from operations? No material adverse divergence — FY26 OCF $6.16B vs GAAP NI $4.76B (OCF > NI, healthy). FCF conversion >100% of net income, aided by working-capital efficiency. The FY27 FCF step-down (~13%) is the item to watch.

Risks & Downside

What would cause the stock to decline? A CVS contract loss/renegotiation (~24% of revenue); evidence the EPS algorithm is buyback-dependent as operating growth fades; ASP/biosimilar profit leakage in oncology; an oncology-MSO impairment; or a market de-rating of the multiple toward 13–14x.

Risk of catastrophic loss? Low — investment-grade balance sheet, utility-like cash flows, opioid provisioned. The realistic downside is a valuation de-rating (bear ~$550–620, a ~20–30% drawdown), not insolvency.

Chance of a total loss? Negligible — a systemically important, profitable, IG-rated, ~$94B leader in a protected oligopoly. (Interpretation.)

Recent News & Events

Has the business environment changed recently? Yes, constructively: (1) MedSurg separation advancing (Apollo 13% at ~$13B EV; planned IPO); (2) Europe exit completed (Norway sold Jan 2026, +$480M); (3) four-segment reorganization for transparency; (4) CFO transition (Kenny Cheung ex-Sysco, May 2026) and CEO assuming Chairman; (5) first IRA branded-price wave navigated with no profit impact. The news tape was otherwise quiet — the only notable item was Barclays trimming its target to $925 (still Overweight, June 10, 2026).

Significant acquisitions? Core Ventures and PRISM Vision (Q1 FY26) — see above.

Change in accounting policies? Segment reorganization (FY26) — presentation, not policy. LIFO credits and one-time gains noted.

Recent changes — new markets, facilities, management? New AI/robotics Montreal distribution center; exited Europe; new CFO; CEO now Chairman; US Oncology Network +570 providers.

APPENDIX B — Source Appendix — McKesson Corporation (NYSE: MCK)

All sources accessed 2026-06-12/13 unless noted. Primary sources (SEC filings, company calls) prioritized over secondary.

Primary — SEC filings (EDGAR, CIK 0000927653)

1. McKesson FY2026 Form 10-K (fiscal year ended March 31, 2026; filed 2026-05-08). https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm
   • Segment revenue/operating-profit tables (North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions, Other).
   • Customer concentration: CVS ~24% of FY26 revenue, ~21% of trade receivables; top 10 ~73% of revenue, ~43% of receivables.
   • Opioid: Note 17 — $5.7B accrued liability for opioid-related claims at 3/31/26; FY26 charge $108M.
2. McKesson FY2025 Form 10-K (filed 2025-05-09). https://www.sec.gov/Archives/edgar/data/927653/000092765325000036/mck-20250331.htm
3. McKesson FY2024 / FY2023 / FY2022 Form 10-K (filed 2024-05-08 / 2023-05-09 / 2022-05-09) — multi-year financial history.
4. McKesson 2026 DEF 14A (proxy) (filed 2026-06-12). https://www.sec.gov/Archives/edgar/data/927653/000092765326… — executive compensation (CEO Tyler ~$24.2M FY26, ~93% variable), MIP metrics (adj EPS 50% / adj OP 25% / FCF 25%), PSU metrics (3-yr cum adj EPS 60% + avg ROIC + rTSR ±20% modifier; 14-company comparator), say-on-pay ~91%, insider ownership <1%, BlackRock 7.9% / Vanguard 7.8%, CFO transition (Kenny Cheung, ex-Sysco, eff. May 29 2026), Tyler combined Chair/CEO, Caruso Lead Independent Director.
5. Form 4 corpus — 291 filings, 2021-06 to 2026-06 (EDGAR submissions JSON, CIK 0000927653). Transaction-code totals: 0 open-market purchases (P); 190 sales (S); 308 exercises (M); 159 tax-withholdings (F); 134 grants (A). Zero open-market insider buys.
6. EDGAR XBRL company facts (https://data.sec.gov/api/xbrl/companyfacts/CIK0000927653.json) — multi-year revenue, gross profit, operating income, net income, EPS, shares outstanding, operating cash flow, capex, repurchases, dividends, stockholders’ equity, goodwill, assets.

Primary — earnings calls & investor events

7. McKesson Q4 FY2026 Earnings Call (May 7, 2026) — FY26 results (rev $403B +12%, adj op profit $6.5B +15%, adj EPS $39.11 +18%, FCF $5.4B, ROIC ~34%, ~$23B returned since FY20); FY27 guidance (adj EPS $43.80–44.60; segment guides; FCF $4.5–4.9B; buyback ~$5B; shares 116–118M; tax 17–19%); MedSurg/Apollo separation; GLP-1 ($53B FY26 distribution rev); CFO retirement.
8. McKesson Q3 FY2026 Earnings Call (Feb 4, 2026) and Q2 FY2026 (Nov 5, 2025) — quarterly trajectory, GLP-1/biosimilar commentary.
9. McKesson Analyst/Investor Day (Sep 23, 2025) — long-range plan framing, specialty/oncology strategy.
10. McKesson conference presentations (BofA May 2026, Leerink/Barclays Mar 2026, JPM Jan 2026, Evercore Dec 2025, UBS Nov 2025) — management framing of segments, GLP-1, biosimilars, capital allocation.

Quantitative data helpers

11. Market data (Yahoo Finance / public aggregators) — price ~$784 (2026-06-12), market cap ~$94B, EV ~$101B, fwd P/E ~15.6x, trailing P/E ~20.4x, EV/EBITDA ~14.6x, beta 0.355, 52-wk $637–999. Unofficial; reconciled to filings.
12. Public valuation/ownership data — GICS Health Care Distributors, ~41,600 employees, March FY-end; valuation percentiles vs own 10-yr history (P/E ~42nd, P/S ~87th); short interest ~2.3% of float; institutions ~93.5%; analyst ratings ~13 buy / 3 hold / 1 sell, mean target ~$950. Third-party aggregated; reconciled to EDGAR.
13. Analyst action — Barclays maintains Overweight, lowers target to $925 (2026-06-10).

Secondary / industry & peer

14. Cencora, Inc. (COR) public filings (FY2025 10-K, FY2026 quarterly) — US drug-distribution industry structure, Big-3 share/comparison, IRA/biosimilar/distribution-service-agreement mechanics, oncology-MSO capital-cycle framing. Cross-read peer.
15. CVS Health, UnitedHealth, Humana public filings — payer/PBM context relevant to McKesson’s customer base and channel dynamics.
16. Healthcare Distribution Alliance — channel value-add estimates (~$78–80B/yr at <1% of brand drug cost).
17. Analytical frameworks — Greenwald & Kahn, Competition Demystified (economies-of-scale + customer-captivity moat, ROIC test, share-stability test); Marathon Asset Management / Chancellor, Capital Returns (capital-cycle lens on the oncology-MSO roll-up).

Note: management commentary is treated as a hypothesis and validated against filings and external data. Third-party AI sentiment/valuation signals are triage inputs, not evidence.